301 related articles for article (PubMed ID: 20187154)
1. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Li J; An L; Zhang Z
Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.
Yang DH; Chang DM; Lai JH; Lin FH; Chen CH
Rheumatology (Oxford); 2009 Sep; 48(9):1083-7. PubMed ID: 19553377
[TBL] [Abstract][Full Text] [Related]
5. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
[TBL] [Abstract][Full Text] [Related]
6. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM
Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
[TBL] [Abstract][Full Text] [Related]
7. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?
Lood C; Eriksson S; Gullstrand B; Jönsen A; Sturfelt G; Truedsson L; Bengtsson AA
Lupus; 2012 Nov; 21(13):1423-32. PubMed ID: 22878256
[TBL] [Abstract][Full Text] [Related]
8. Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Singh V; Mahoney JA; Petri M
J Rheumatol; 2008 Oct; 35(10):1989-93. PubMed ID: 18709693
[TBL] [Abstract][Full Text] [Related]
9. Urinary C3d is elevated in patients with active Lupus nephritis and a fall in its level after 3 months predicts response at 6 months on follow up.
Ganguly S; Majumder S; Kumar S; Gupta R; Muhammed H; Shobha V; Aggarwal A; Misra R
Lupus; 2020 Nov; 29(13):1800-1806. PubMed ID: 32807020
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Senaldi G; Makinde VA; Vergani D; Isenberg DA
Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
[TBL] [Abstract][Full Text] [Related]
11. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome.
Hammond A; Rudge AC; Loizou S; Bowcock SJ; Walport MJ
Arthritis Rheum; 1989 Mar; 32(3):259-64. PubMed ID: 2522783
[TBL] [Abstract][Full Text] [Related]
12. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
[TBL] [Abstract][Full Text] [Related]
13. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Manzi S; Navratil JS; Ruffing MJ; Liu CC; Danchenko N; Nilson SE; Krishnaswami S; King DE; Kao AH; Ahearn JM
Arthritis Rheum; 2004 Nov; 50(11):3596-604. PubMed ID: 15529364
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.
Merrill JT; Petri MA; Buyon J; Ramsey-Goldman R; Kalunian K; Putterman C; Conklin J; Furie RA; Dervieux T
Lupus Sci Med; 2018; 5(1):e000263. PubMed ID: 29868177
[TBL] [Abstract][Full Text] [Related]
15. Platelet C4d is highly specific for systemic lupus erythematosus.
Navratil JS; Manzi S; Kao AH; Krishnaswami S; Liu CC; Ruffing MJ; Shaw PS; Nilson AC; Dryden ER; Johnson JJ; Ahearn JM
Arthritis Rheum; 2006 Feb; 54(2):670-4. PubMed ID: 16447243
[TBL] [Abstract][Full Text] [Related]
16. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
Röther E; Lang B; Coldewey R; Hartung K; Peter HH
Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
[TBL] [Abstract][Full Text] [Related]
17. A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes.
Freysdottir J; Sigfusson A
J Immunol Methods; 1991 Aug; 142(1):45-52. PubMed ID: 1833467
[TBL] [Abstract][Full Text] [Related]
18. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
19. Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.
Martin M; Smoląg KI; Björk A; Gullstrand B; Okrój M; Leffler J; Jönsen A; Bengtsson AA; Blom AM
Arthritis Res Ther; 2017 Dec; 19(1):266. PubMed ID: 29208014
[TBL] [Abstract][Full Text] [Related]
20. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
